Prosecution Insights
Last updated: April 19, 2026
Application No. 18/208,672

PROTEIN-TEMPLATED SELF-ASSEMBLY OF A COVALENT POLYMER NETWORK FOR INTRACELLULAR TRAFFICKING AND TRACELESS RELEASE

Non-Final OA §103
Filed
Jun 12, 2023
Examiner
ROGERS, JAMES WILLIAM
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
UNIVERSITY OF MASSACHUSETTS
OA Round
1 (Non-Final)
46%
Grant Probability
Moderate
1-2
OA Rounds
3y 10m
To Grant
68%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allow Rate
413 granted / 891 resolved
-13.6% vs TC avg
Strong +22% interview lift
Without
With
+21.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
50 currently pending
Career history
941
Total Applications
across all art units

Statute-Specific Performance

§101
0.2%
-39.8% vs TC avg
§103
41.5%
+1.5% vs TC avg
§102
26.0%
-14.0% vs TC avg
§112
22.6%
-17.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 891 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim 32-41 and 44 is/are rejected under 35 U.S.C. 103 as being unpatentable over Matsumoto et al. "Synthesis of nanogel–protein conjugates", Polym. Chem., 2013, 4, 2464–2469, cited parent application 16/497,145, alone or in view of Topala et al. "BOVINE SERUM ALBUMIN INTERACTIONS WITH METAL COMPLEXES", Clujul Medical 2014 Vol. 87 - no. 4, cited parent application 16/497,145 Matsumoto teaches polymer protein conjugates of the following formula: PNG media_image1.png 183 286 media_image1.png Greyscale , crosslinked by dithiothreitol. See entire disclosure, especially abstract and Fig 2. Matsumoto while teaching a free amino acid is used to form a bond with a linker (SATP) it is silent with respect to the specific amino acid such as lysine required in the claims. See paragraph bridging page 2464 and 2465. Matsumoto however does teach that for covalent attachment lysine is commonly exploited. Thus one of ordinary skill in the art would have a high expectation of success in using lysine to bind the protein to the polymer. Reason to do so stems from the suggestion of Matsumoto that lysine is useful in forming such covalent attachment. Regarding claim 44, Matsumoto teaches and suggest that the polymer-conjugate could be used with an antibody as the protein increasing its effectiveness. Topala teaches the protein used by Matsumoto, bovine serum albumin (BSA), is abundant in ionic amino acids such as lysine. See page 216 left col. 1st full paragraph. Thus from the disclosure of Matsumoto that lysine was a well-known reactive amino acid and the teaching from Topala that lysine is abundant in BSA one of ordinary skill would have a high expectation of success in using lysine to bind the protein to the polymer by linker. Claim 32-41,44 and 47-55 is/are rejected under 35 U.S.C. 103 as being unpatentable over Matsumoto et al., cited above, in view of Topala, cited above, in view of Leng et al. “Probing the Surface Hydration of Nonfouling Zwitterionic and PEG Materials in Contact with Proteins”, ACS Appl. Mater. Interfaces 2015, 7, 16881−16888, in view of Peng et al. “Grafting of silica with a hydrophilic triolacrylamide polymer via surface-initiated‘‘grafting from’’ method for hydrophilic interaction chromatography” J. Sep. Sci. 2011, 34, 3123–3130, in view of Powell et al. “Complex Amphiphilic Hyperbranched Fluoropolymers by Atom Transfer Radical Self-Condensing Vinyl (Co)polymerization”, Macromolecules 2007, 40, 4509-4515. Matsumoto is disclosed above. While the formula of Matsumoto above reads on formula II and III and the linkage of claim 48-49,51 and 53 the reference is silent with respect to use of a zwitterionic group including those of claim 50. The reference while teaching side chain substituted hydrophilic groups is silent with respect to Tris(hydroxymethyl)aminomethane as recited in claim 52. Lastly while teaching dithiol substituted side chains the reference is silent with respect to the dithiol grated with substituted benzenes of claim 54 which include fluorobenzene. Leng is used for its teaching on the use of zwitterionic side chains on methacrylate, including sulfobetaine (meeting claim 50), were well known before the time of the claimed invention. See entire disclosure, especially abstract and Fig. 1. The zwitterionic species increased the surface hydration and non-fouling properties of surfaces in contact with proteins. Peng is used for its teaching on the use of the functional group Tris(hydroxymethyl)aminomethane grafted on polymers which enhanced hydrophilicity. See entire disclosure, especially abstract and Fig. 2. Powell is used for its teaching on the use of fluorinated benzene groups (meeting claim 54) in polymer synthesis, produced a polymer that was soluble in a broad range of solvents. See entire disclosure, especially abstract and scheme 1. Since Matsumoto already teaches how to attach various groups to the methacrylate backbone via standard chemistry one of ordinary skill in the art would have a high expectation of success in grafting the zwitterionic, hydrophilic and fluorinated benzene groups from Leng, Peng and Powell respectfully. Reason to make such a modification would be to adjust the properties of the polymer including its anti-fouling ability, hydrophilicity and solubility. Thus the claimed invention would have been prima facie obvious since all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions and the combination would have yielded predictable results to one of ordinary skill in the art at the time of the invention. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAMES W ROGERS whose telephone number is (571)272-7838. The examiner can normally be reached 9:30-6:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAMES W ROGERS/Primary Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Jun 12, 2023
Application Filed
Mar 04, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594345
DEGRADABLE HYALURONIC ACID HYDROGELS
2y 5m to grant Granted Apr 07, 2026
Patent 12582727
CHEMILUMINESCENT AND FLUORESCENT NANOPARTICLE FOR OPTICAL IMAGING OF CANCER
2y 5m to grant Granted Mar 24, 2026
Patent 12582744
DRESSINGS COMPRISING PLATELET LYSATE
2y 5m to grant Granted Mar 24, 2026
Patent 12565506
NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS
2y 5m to grant Granted Mar 03, 2026
Patent 12544335
TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULES
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
46%
Grant Probability
68%
With Interview (+21.6%)
3y 10m
Median Time to Grant
Low
PTA Risk
Based on 891 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month